EUVIMEDEUVIMED entdecken
Crossref

18F-Sodium Fluoride PET/CT as a Tool to Assess Enthesopathies in X-Linked Hypophosphatemia

Macarena Jimenez, Aaron J Sheppard, Rodrigo Jaimovich, Natalia Covarrubias, Diego Jordan, Juan Carlos Quintana, Oscar Contreras, Danisa Ivanovic Zuvic, Anette Madison, Babak Saboury, Michael T Collins, Pablo Florenzano iD

Calcified Tissue International · 2025

DOI: 10.1007/s00223-025-01343-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Calcified Tissue International, 2025. Verfasst von Macarena Jimenez und 11 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Department, School of Medicine, Pontificia Universidad Católica de Chile, Av. Diagonal Paraguay 262, Cuarto Piso, Santiago, Chile. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Sodium Fluoride, Enthesopathy, Familial Hypophosphatemic Rickets. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Ultragenyx Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

X-linked hypophosphatemia (XLH) is a rare metabolic disorder characterized by elevated FGF23 and chronic hypophosphatemia, leading to impaired skeletal mineralization and enthesopathies that are associated with pain, stiffness, and diminished quality of life. The natural history of enthesopathies in XLH remains poorly defined, partly due to absence of a sensitive quantitative tool for assessment and monitoring. This study investigates the utility of 18F-NaF PET/CT scans in characterizing enthesopathies in XLH subjects. In 19 adult XLH subjects, enthesopathy burden was assessed by quantifying calcified sites on CT and 18F-NaF PET uptake at 16 common tendon/ligament insertion locations. Parameters obtained were (1) number of enthesopathy sites, (2) characterization of each site as CT-positive (CT +) and/or PET-positive (PET +), (3) a semiquantitative score based on severity of affected enthesopathies (CT-scoreglobal and PET-scoreglobal). Biochemical and self-reported questionnaires results were correlated with 18F-NaF PET/CT parameters. 18F-NaF PET/CT detected at least one enthesopathy in all subjects, with 18F-NaF PET positivity often detected before CT (19.4% of all enthesopathies). Age negatively correlated with the number of PET + /CT- enthesopathies and positively with PET-/CT + enthesopathies. PET-scoreglobal was positively associated with ALP. While PET-scoreglobal showed no correlation with any applied survey, CT-scoreglobal was associated with worse functionality and pain. These associations suggest a progression from an actively mineralizing lesion to a more established, inactive lesion. Overall, although 18F-NaF PET/CT is not yet indicated for routine clinical use, it is a promising research tool for evaluating enthesopathy burden in XLH, offering valuable insights into the disease's progression and potentially enabling early therapeutic assessment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographySodium FluorideEnthesopathyFamilial Hypophosphatemic RicketsHumansMaleFemaleAdultMiddle AgedFibroblast Growth Factor-23Fluorine RadioisotopesYoung AdultAged

Stichwörter der Autor:innen

EnthesopathyExtra-skeletal calcificationsFibroblast growth factor 23 (FGF23)Osteomalacia and ricketsX‐linked hypophosphatemia (XLH)

Substanzen

Sodium FluorideFibroblast Growth Factor-23Fluorine RadioisotopesFGF23 protein, human

Autor:innen und Institutionen

  • Endocrinology Department, School of Medicine, Pontificia Universidad Católica de Chile, Av. Diagonal Paraguay 262, Cuarto Piso, Santiago, Chile.
  • Center for Translational Research in Endocrinology, School of Medicine, CETREN-UC, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Skeletal Disorders and Mineral Homeostasis Section, National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD, USA.
  • School of Medicine, Louisiana State University Health Shreveport, Shreveport, LA, USA.
  • Radiology and Nuclear Medicine Department, School of Medicine, Universidad Católica de Chile, Santiago, Chile.
  • Endocrinology Department, Hospital del Salvador, Santiago, Chile.

ORCID-Profile: Pablo Florenzano

Förderung

  • Ultragenyx Pharmaceutical

Zitieren

APA

Jimenez, M., Sheppard, A. J., Jaimovich, R., Covarrubias, N., Jordan, D., Quintana, J. C., Contreras, O., Zuvic, D. I., Madison, A., Saboury, B., Collins, M. T., & Florenzano, P. (2025). 18F-Sodium Fluoride PET/CT as a Tool to Assess Enthesopathies in X-Linked Hypophosphatemia. Calcified Tissue International. https://doi.org/10.1007/s00223-025-01343-3

Vancouver

Jimenez M, Sheppard AJ, Jaimovich R, Covarrubias N, Jordan D, Quintana JC, et al. 18F-Sodium Fluoride PET/CT as a Tool to Assess Enthesopathies in X-Linked Hypophosphatemia. Calcified Tissue International. 2025. doi:10.1007/s00223-025-01343-3

BibTeX
@article{Jimenez2025,
  author = {Jimenez, Macarena and Sheppard, Aaron J and Jaimovich, Rodrigo and Covarrubias, Natalia and Jordan, Diego and Quintana, Juan Carlos and Contreras, Oscar and Zuvic, Danisa Ivanovic and Madison, Anette and Saboury, Babak and Collins, Michael T and Florenzano, Pablo},
  title = {18F-Sodium Fluoride PET/CT as a Tool to Assess Enthesopathies in X-Linked Hypophosphatemia},
  journal = {Calcified Tissue International},
  year = {2025},
  doi = {10.1007/s00223-025-01343-3}
}
Kostenlos starten →